Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07336446 · ClinicalTrials.gov registry record · Phase 1
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
A Phase 1 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
NCT07336446 is a Phase 1 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 300 participants.
The verdict
NCT07336446, a Phase 1 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
Study Summary
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
Interventions
- DRUG AZD5305
- DRUG AZD9750
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2029-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07336446
The ClinicalTrials.gov registry entry for NCT07336446 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD5305 is the first listed.
NCT07336446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07336446 about?
NCT07336446 is a clinical study titled "A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs". ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
What is the current status of trial NCT07336446?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2026-01-27. Estimated completion is 2029-01-26.
What interventions are being tested in trial NCT07336446?
The interventions under investigation include: AZD5305 (DRUG), AZD9750 (DRUG).
Who is sponsoring clinical trial NCT07336446?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.